Loading
Governments and foundations would pool a prize of about a billion dollars into an escrowed fund, paid only when a treatment is shown in a well-controlled registration cohort to keep most patients with a currently incurable metastatic cancer, such as pancreatic adenocarcinoma or glioblastoma, disease-free for five years. The winner keeps its patent but accepts a price ceiling.
A pull incentive that pays for the outcome the system currently under-rewards. The prize is defined in advance per disease (for example metastatic pancreatic adenocarcinoma, glioblastoma, metastatic TNBC) with an objective bar such as at least 50% five-year disease-free survival in a randomised or well-controlled registration cohort where the historical figure is under 5%. The winner keeps its patent but accepts a price ceiling and global access licensing as a condition. Multiple sponsors could pool into a single escrowed fund; a partial prize could be paid for intermediate milestones (for example 25% durable remission).
Shares Incentives reward me-too drugs and marginal gains, Glioma & glioblastoma, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares Milestone prizes for first-in-class mechanisms reaching human proof of concept, Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares Milestone prizes for first-in-class mechanisms reaching human proof of concept, Incentives reward me-too drugs and marginal gains.
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
Shares Metastasis is understood least and studied last, Triple-negative breast cancer (TNBC).